Powell’s ‘been dealt an insanely bad hand’ in the inflation fight, Jim Cramer says


CNBC’s Jim Cramer defended Federal Reserve Chair Jerome Powell Monday after the central bank chief promised aggressive action on inflation.

“Powell’s been dealt an insanely bad hand. So of course he’s fallen behind. Hence why he’s said that the Fed will move with alacrity from here on out,” the “Mad Money” host said. “So feel free to blame him for not seeing what was coming. If he has to do a [50 basis point interest rate hike], he will.”

“Never forget that Powell’s been asked to do the impossible here: Figure out how fast to raise interest rates when so many things should be slowing the economy and cooling inflation naturally, yet nothing has worked out the way we expected,” he added.

Powell on Monday pledged that the Fed will take strong action against surging inflation, which is currently at its highest level in 40 years. Powell said rate hikes bigger than a quarter-percentage point are possible and hikes will continue until inflation is under control.

His strong stance against inflation, which comes one week after the Fed raised interest rates for the first time in more than three years, led the market to teeter Monday, ending a multiday streak of gains. The Dow Jones Industrial Average dipped 0.6%, while the S&P 500 slipped 0.04%. The Nasdaq Composite dropped 0.4%.

Listing a bevy of recent market shakers — including the current housing shortage, the semiconductor chip shortage, healthy consumer spending, Covid fears and Russia’s invasion of Ukraine — Cramer reiterated that these unprecedented times have made it difficult for Powell to anticipate what will strike the market next.

Cramer added that he believes it’s unfair for investors to expect Powell to predict the path of the pandemic.

“At the end of the day, public health is outside of the Fed’s purview,” Cramer said.



Source

FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More
Toyota, Hyundai and Chinese automakers expected to be most impacted by Iran war
Business

Toyota, Hyundai and Chinese automakers expected to be most impacted by Iran war

Toyota Motor Corp. vehicles bound for shipment at the Port of Nagoya in Tokai, Aichi Prefecture, Japan, on Tuesday, April 29, 2025. Toru Hanai | Bloomberg | Getty Images DETROIT — Toyota Motor, Hyundai Motor and Chinese automakers such as Chery face the most potential impact of non-domestic automakers from the U.S.-Israel war with Iran, […]

Read More
Used vehicle prices jump ahead of spring selling season optimism
Business

Used vehicle prices jump ahead of spring selling season optimism

A used car dealership is seen in Annapolis, Maryland on May 27, 2021, as many car dealerships across the country are running low on new vehicles as a computer chip shortage has caused production at many vehicle manufactures to nearly stop. Jim Watson | AFP | Getty Images DETROIT — A closely watched barometer for used […]

Read More